Monitor the European Commission's final approval decision, expected within ~2 months following CHMP opinion. Also watch for US FDA decision on the same PREVAIL data, which could expand the addressable market significantly.
Price Chart
Executive Summary
AstraZeneca announced that the EMA's CHMP has recommended Klygefa (gefurulimab) for EU approval as an add-on therapy for adults with AChR antibody-positive generalized myasthenia gravis. The recommendation is based on the Phase III PREVAIL trial showing a statistically significant improvement in MG-ADL score vs placebo (treatment difference -1.6, p<0.0001). If approved, Klygefa would be the first dual-binding nanobody C5 inhibitor for gMG in the EU, offering once-weekly subcutaneous self-administration.
Key Facts
- CHMP recommended Klygefa (gefurulimab) for EU approval in AChR antibody-positive generalized myasthenia gravis
- Recommendation based on Phase III PREVAIL trial: MG-ADL treatment difference -1.6 (95% CI: -2.4, -0.8, p<0.0001) at week 26
- If approved, Klygefa will be the first and only dual-binding nanobody C5 inhibitor for gMG in the EU
- Klygefa is already approved in Japan and other countries; regulatory submissions under review in the US, China, and additional countries
- Estimated 66,000 AChR-positive gMG patients in five major EU countries
Financial Impact
No revenue or financial figures provided in the filing; Klygefa adds to AstraZeneca's rare disease pipeline with potential EU market access for ~66,000 AChR-positive gMG patients
Risk Factors
- European Commission may not follow CHMP recommendation, though this is rare
- Competition from existing C5 inhibitors (Soliris, Ultomiris) and other gMG therapies may limit uptake
- Pricing and reimbursement negotiations in EU countries could affect commercial potential
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-008478 |
| Document: 0001654954-26-008478-index-headers.html | 0001654954-26-008478 |
| Document: 0001654954-26-008478-index.html | 0001654954-26-008478 |
| Document: 0001654954-26-008478.txt | 0001654954-26-008478 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $172.57 $171.49 | ▼ −0.63% | ▼ −0.10% | $172.06 (−0.30%) |
Oct 15, 2026 12d ago | Court Ruling | $165.41 $163.95 | ▼ −0.88% | ▼ −1.31% | $172.06 (+4.02%) |
Oct 5, 2026 21d ago | 6-K | $156.53 $158.61 | ▲ +1.33% | ▲ +0.78% | $172.06 (+9.92%) |
Oct 2, 2026 24d ago | 6-K | $156.90 $156.53 | ▼ −0.24% | ▼ −0.91% | $172.06 (+9.66%) |
Oct 2, 2026 25d ago | Court Ruling | $156.53 $158.61 | ▲ +1.33% | ▲ +0.78% | $172.06 (+9.92%) |
Oct 1, 2026 25d ago | 6-K | $157.70 $156.90 | ▼ −0.51% | ▼ −1.25% | $172.06 (+9.11%) |
Oct 1, 2026 25d ago | 6-K | $157.70 $156.90 | ▼ −0.51% | ▼ −1.25% | $172.06 (+9.11%) |
Sep 29, 2026 27d ago | 6-K | $164.21 $161.47 | ▼ −1.67% | ▼ −1.46% | $172.06 (+4.78%) |
Sep 23, 2026 4w ago | 6-K | $163.33 $164.56 | ▲ +0.75% | ▲ +0.84% | $172.06 (+5.35%) |
Sep 21, 2026 5w ago | 6-K | $168.10 $168.37 | ▲ +0.16% | ▲ +0.18% | $172.06 (+2.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers